A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)
Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate MK0457 in patients with chronic myelogenous leukemia and
Philadelphia chromosome-positive acute lymphoblastic leukemia. Efficacy and safety will be
evaluated.